Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Astrana Health, Inc. Reports First Quarter 2026 Results

      Astrana Health Logo (PRNewsfoto/Astrana Health, Inc.)

      News provided by

      Astrana Health, Inc.

      May 07, 2026, 16:05 ET

      Share this article

      Share this article


      Company to Host Conference Call on Thursday, May 7, 2026, at 2:30 p.m. PT/5:30 p.m. ET

      • Reports total revenue of $965.1 million, up 56% year over year
      • Reports adjusted EBITDA(1) of $66.3 million, up 82% year over year and free cash flow(2) of $64.1 million, up 372% year over year

      ALHAMBRA, Calif., May 7, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the first quarter ended March 31, 2026.

      "We had a strong start to 2026, delivering disciplined growth, strong medical cost performance, continued operating leverage, and early performance from new full-risk contracts in line with our expectations," said Brandon Sim, President and Chief Executive Officer of Astrana Health. "In an increasingly dynamic healthcare environment, we believe advantage will accrue to organizations that can integrate care delivery, data, and financial accountability into a single operating system. Astrana has built exactly that: a proprietary healthcare operating platform that enables us to embed AI and workflow orchestration directly into clinical and operational workflows across the enterprise. Combined with our longitudinal patient relationships and data continuity, our infrastructure allows us to translate AI into durable clinical and economic value while continuing to improve patient outcomes, operating efficiency, and scalability. We believe Astrana is well positioned to continue widening that advantage over time."

      Financial Highlights for First Quarter Ended March 31, 2026:

      All comparisons are to the three months ended March 31, 2025 unless otherwise stated.

      • Total revenue of $965.1 million, up 56% from $620.4 million
      • Care Partners revenue of $909.7 million, up 51% from $601.0 million
      • Net income attributable to Astrana of $14.4 million, up 116% from $6.7 million
      • Earnings per share ("EPS") - diluted of $0.29, up 107% from $0.14
      • Adjusted EBITDA(1) of $66.3 million, up 82% from $36.4 million
      • Adjusted EPS - diluted(3) of $0.74, up 76% from $0.42
      • Net cash provided by operating activities of $68.1 million, up 309% from $16.6 million
      • Free cash flow(2) of $64.1 million, up 372% from $13.6 million

      (1)

      See "Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin" and "Use of Non-GAAP Financial Measures" below for additional information.

      (2)

      See reconciliation provided with the condensed consolidated statements of cash flow and "Use of Non-GAAP Financial Measures" below for additional information.

      (3)

      See "Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted" and "Use of Non-GAAP Financial Measures" below for additional information.

      Recent Operating Highlights

      • Delivered on its commitment to convert key contracts to full-risk arrangements, with approximately 80% of Care Partners capitation revenue and approximately 40% of consolidated membership now in full-risk arrangements.
      • Launched Astrana's delegated full-risk model with a payer partner in Texas, expanding Medicare Advantage membership in the market to more than 14,000 members.
      • Continued deleveraging ahead of schedule, with net leverage declining to approximately 2.3x on a pro forma trailing twelve-month basis and to 2.2x based on the midpoint of the Company's full-year guidance.
      • Foothill Regional Medical Center ("FRMC") received Healthgrades' 2026 Patient Safety Excellence Award™ for the fourth consecutive year and was named among Healthgrades' America's 100 Best Hospitals for Joint Replacement in 2026. FRMC also received the Healthgrades Joint Replacement Excellence Award for the second consecutive year, reflecting continued strength in clinical quality and patient outcomes.

      Segment Results for three months ended March 31, 2026:

      All comparisons are to the three months ended March 31, 2025 unless otherwise stated.



      Three Months Ended March 31, 2026


      (in thousands)


      Care
      Partners



      Care
      Delivery



      Care
      Enablement



      Intersegment
      Elimination



      Corporate
      Costs



      Consolidated
      Total


      Total revenues


      $

      909,703



      $

      85,077



      $

      87,745



      $

      (117,425)



      $

      —



      $

      965,100


      % change vs. prior year quarter



      51

      %



      155

      %



      122

      %





























      Cost of services



      785,531




      72,544




      48,704




      (47,423)




      —




      859,356


      General and administrative expenses



      72,546




      14,374




      17,259




      (69,974)




      27,532




      61,737


      Depreciation and amortization



      12,170




      1,122




      1,629




      —




      558




      15,479


      Total expenses



      870,247




      88,040




      67,592




      (117,397)




      28,090




      936,572





















      Income (loss) from operations


      $

      39,456



      $

      (2,963)



      $

      20,153



      $

      (28)


      (1)

      $

      (28,090)



      $

      28,528


      % change vs. prior year quarter



      (11)

      %



      (5)

      %



      470

      %












      (1)

      Loss from operations for the intersegment elimination represents sublease income between segments. Sublease income is presented within other income, which is not presented in the table. 

      2026 Guidance:

      Astrana is providing the following guidance for total revenue and Adjusted EBITDA for the quarter ending June 30, 2026 and reiterating guidance for the year ending December 31, 2026 based on the Company's existing business, current view of existing market conditions, and assumptions.



      Three Months Ending
      June 30, 2026



      Year Ending
      December 31, 2026




      Guidance Range



      Guidance Range


      ($ in millions)


      Low



      High



      Low



      High


      Total revenue


      $

      965



      $

      1,000



      $

      3,800



      $

      4,100


      Adjusted EBITDA


      $

      65



      $

      70



      $

      250



      $

      280


      Free cash flow








      $

      105



      $

      132.5


      See "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA," "Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow," and "Use of Non-GAAP Financial Measures" below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" below for additional information.

      Conference Call and Webcast Information:

      Astrana will host a conference call at 2:30 p.m. PT/5:30 p.m. ET today (Thursday, May 7, 2026), during which management will discuss the results of the first quarter ended March 31, 2026. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:

      U.S. & Canada (Toll-Free):

      +1 (877) 858-9810

      International (Toll):

      +1 (201) 689-8517

      The conference call can also be accessed via webcast at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=HHhCPjaF

      An accompanying slide presentation will be available in PDF format on the "IR Calendar" page of the Company's website (https://ir.astranahealth.com/news-events/ir-calendar) after issuance of the earnings release and will be furnished as an exhibit to Astrana's current report on Form 8-K to be filed with the SEC, accessible at www.sec.gov. 

      Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.

      Note About Consolidated Entities

      The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities ("VIEs") in which the Company is the primary beneficiary. Non-controlling interests represent third party equity ownership interests in the Company's consolidated entities (including certain VIEs). The amount of net income or loss attributable to non-controlling interests is disclosed in the Company's consolidated statements of income.

      About Astrana Health, Inc.

      Astrana Health is a physician-centric, AI-powered healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across the healthcare system.

      Today, Astrana supports more than 20,000 providers and approximately 1.55 million patients in value-based care arrangements through its affiliated provider networks, management services organization, and integrated care delivery clinics spanning primary, specialty, and ancillary care. Together, Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for all. For more information, visit www.astranahealth.com. 

      Forward-Looking Statements

      This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company's guidance for the quarter ending June 30, 2026 and the year ending  December 31, 2026, ability to meet operational goals, ability to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving quality and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing environment, statements about the Company's liquidity, and successful completion and implementation of strategic growth plans, acquisition strategy, and merger integration efforts, as well as statements regarding the material weakness in internal control over financial reporting and the Company's ability to remediate such material weakness in a timely manner. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the SEC, including, without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent quarterly reports on Form 10-Q. Any forward-looking statements made by the Company in this release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

      FOR MORE INFORMATION, PLEASE CONTACT:

      Carolyne Sohn, Investor Relations
      [email protected] 

      ASTRANA HEALTH, INC.

      CONDENSED CONSOLIDATED BALANCE SHEETS

      (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)




      March 31,
      2026



      December 31,
      2025




      (Unaudited)





      Assets














      Current assets







      Cash and cash equivalents


      $

      478,383



      $

      429,474


      Receivables, net (including amounts from related parties)



      467,395




      374,465


      Income taxes receivable



      —




      1,799


      Other receivables



      28,017




      26,385


      Prepaid expenses and other current assets



      25,647




      26,264


      Loans receivable



      4,658




      4,926









      Total current assets



      1,004,100




      863,313









      Non-current assets







      Property and equipment, net



      59,546




      57,332


      Intangible assets, net



      257,118




      270,968


      Goodwill



      874,799




      865,305


      Income taxes receivable, net of current portion



      26,220




      26,220


      Loans receivable, net of current portion



      49,068




      48,724


      Investments in other entities – equity method



      27,257




      25,637


      Operating lease right-of-use assets



      33,933




      35,738


      Other assets



      26,786




      25,424









      Total non-current assets



      1,354,727




      1,355,348









      Total assets (1)


      $

      2,358,827



      $

      2,218,661









      Liabilities, Mezzanine Deficit, and Stockholders' Equity














      Current liabilities







      Accounts payable and accrued expenses


      $

      221,389



      $

      195,912


      Fiduciary accounts payable



      3,706




      3,524


      Income taxes payable



      2,507




      —


      Medical liabilities



      439,259




      335,705


      Operating lease liabilities



      7,557




      7,809


      Current portion of long-term debt



      47,865




      47,865


      Other liabilities



      23,086




      24,458









      Total current liabilities



      745,369




      615,273









      Non-current liabilities







      Deferred tax liability



      7,399




      5,491


      Operating lease liabilities, net of current portion



      30,006




      31,552


      Long-term debt, net of current portion and deferred financing costs



      979,764




      990,904


      Other long-term liabilities



      18,833




      17,107









      Total non-current liabilities



      1,036,002




      1,045,054









      Total liabilities (1)



      1,781,371




      1,660,327









      Mezzanine deficit







      Non-controlling interest in Allied Physicians of California, a Professional Medical
      Corporation ("APC")



      (237,739)




      (234,962)









      Stockholders' equity







      Preferred stock, $0.001 par value per share; 5,000,000 shares authorized; and zero
      shares issued and outstanding as of March 31, 2026 and December 31, 2025



      —




      —


      Common stock, $0.001 par value per share; 100,000,000 shares authorized,
      48,946,399 and 48,885,358 shares issued and outstanding, excluding 10,695,758
      and 10,571,011 treasury shares, as of March 31, 2026 and December 31, 2025,
      respectively



      49




      49


      Additional paid-in capital



      477,508




      470,863


      Retained earnings



      322,711




      308,379


      Total stockholders' equity



      800,268




      779,291









      Non-controlling interests



      14,927




      14,005









      Total equity



      815,195




      793,296









      Total liabilities, mezzanine deficit, and stockholders' equity


      $

      2,358,827



      $

      2,218,661




      (1)

      The Company's condensed consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The condensed consolidated balance sheets include (a) total assets of  $1,317.1 million and $1,276.5 million as of March 31, 2026 and December 31, 2025, respectively, that can be used only to settle obligations of the Company's consolidated VIEs and (b) total liabilities of the consolidated VIEs of $394.5 million and $376.0 million as of March 31, 2026 and December 31, 2025, respectively, for which creditors do not have recourse to the general credit of the Company, the VIE's primary beneficiary. These VIE balances do not include $150.4 million of investment in affiliates and $24.4 million of amounts due from affiliates as of March 31, 2026, and $152.2 million of investment in affiliates and $58.3 million of amounts due from affiliates as of December 31, 2025, as these are eliminated upon consolidation and not presented within the condensed consolidated balance sheets.

      ASTRANA HEALTH, INC.

      CONDENSED CONSOLIDATED STATEMENTS OF INCOME

      (IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)

      (UNAUDITED)




      Three Months Ended
      March 31,




      2026



      2025


      Revenue







      Capitation, net


      $

      892,908



      $

      583,963


      Risk pool settlements and incentives



      12,486




      14,491


      Management fee income



      15,685




      2,310


      Fee-for-service, net



      37,831




      14,890


      Other revenue



      6,190




      4,736









      Total revenue



      965,100




      620,390









      Operating expenses







      Cost of services, excluding depreciation and amortization



      859,356




      549,061


      General and administrative expenses



      61,737




      43,897


      Depreciation and amortization



      15,479




      6,849









      Total expenses



      936,572




      599,807









      Income from operations



      28,528




      20,583









      Other (expense) income







      Income (loss) from equity method investments



      1,720




      (867)


      Interest expense



      (16,101)




      (7,308)


      Interest income



      3,816




      2,312


      Unrealized gain (loss) on investments



      1,084




      (44)


      Other income (loss)



      662




      (5,072)









      Total other expense, net



      (8,819)




      (10,979)









      Income before provision for income taxes



      19,709




      9,604









      Provision for income taxes



      6,578




      3,383









      Net income



      13,131




      6,221









      Net loss attributable to non-controlling interests



      (1,305)




      (471)









      Net income attributable to Astrana Health, Inc.


      $

      14,436



      $

      6,692









      Earnings per share – basic


      $

      0.30



      $

      0.14









      Earnings per share – diluted


      $

      0.29



      $

      0.14









      Weighted average shares of common stock outstanding – basic



      48,853,678




      48,470,682









      Weighted average shares of common stock outstanding – diluted



      49,054,135




      48,850,666


      ASTRANA HEALTH, INC.

      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

      (IN THOUSANDS)

      (UNAUDITED)




      Three Months Ended
      March 31,




      2026



      2025


      Cash flows from operating activities







      Net income


      $

      13,131



      $

      6,221


      Adjustments to reconcile net income to net cash provided by operating activities:







      Depreciation and amortization



      15,479




      6,849


      Amortization of debt issuance cost



      1,134




      691


      Share-based compensation



      9,895




      7,811


      Non-cash lease expense



      2,005




      1,287


      Deferred tax



      1,907




      (358)


      Change in fair value of contingent consideration liabilities



      581




      1,407


      Other



      (2,564)




      729


      Changes in operating assets and liabilities, net of business combinations



      26,488




      (8,010)


      Net cash provided by operating activities



      68,056




      16,627









      Cash flows from investing activities







      Purchases of property and equipment



      (4,000)




      (3,070)


      Other



      1,156




      676


      Net cash used in investing activities



      (2,844)




      (2,394)









      Cash flows from financing activities







      Dividends paid



      (104)




      (5,455)


      Borrowings on debt



      —




      412,000


      Repayment of debt



      (11,967)




      (428,232)


      Deferred financing cost



      —




      (17,241)


      Taxes paid from net share settlement of restricted stock



      (1,172)




      (4,052)


      Repurchase of treasury shares



      (2,906)




      —


      Other



      189




      (1,190)


      Net cash used in financing activities



      (15,960)




      (44,170)









      Net increase (decrease) in cash, cash equivalents, and restricted cash



      49,252




      (29,937)









      Cash, cash equivalents, and restricted cash, beginning of period



      434,045




      289,101









      Cash, cash equivalents, and restricted cash, end of period


      $

      483,297



      $

      259,164









      Supplemental disclosures of cash flow information







      Cash paid for income taxes


      (1)



      $

      4,338


      Cash paid for interest


      $

      14,723



      $

      7,360









      Supplemental disclosures of non-cash investing and financing activities







      Right-of-use assets obtained in exchange for operating lease liabilities


      $

      350



      $

      5,729


      Dividend paid in the form of common stock


      $

      —



      $

      21,935




      (1)

      Following the adoption of ASC 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures", cash paid for income taxes is presented net of tax refunds, for the quarter ended March 31, 2026, under Item 1 of the Company's Quarterly Report on Form 10-Q.

      The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total amounts of cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows (in thousands):



      March 31,




      2026



      2025


      Cash and cash equivalents


      $

      478,383



      $

      258,517


      Restricted cash (1)



      4,914




      647


      Total cash, cash equivalents, and restricted cash shown in the statement of cash
      flows


      $

      483,297



      $

      259,164




      (1)

      Restricted cash is included in other assets on the condensed consolidated balance sheets. 

      Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow




      Three Months Ended
      March 31,



      (in thousands)


      2026



      2025



      Net cash provided by operating activities


      $

      68,056



      $

      16,627



      Purchases of property and equipment



      (4,000)




      (3,070)



      Free cash flow


      $

      64,056



      $

      13,557



      Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin

      Set forth below are reconciliations of Net Income to EBITDA and Adjusted EBITDA, as well as the reconciliations to Adjusted EBITDA margin for the three months ended March 31, 2026 and 2025. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.



      Three Months Ended
      March 31,



      (in thousands)


      2026



      2025



      Net income


      $

      13,131



      $

      6,221



      Interest expense



      16,101




      7,308



      Interest income



      (3,816)




      (2,312)



      Provision for income taxes



      6,578




      3,383



      Depreciation and amortization



      15,479




      6,849



      EBITDA



      47,473




      21,449











      (Income) loss from equity method investments



      (1,720)




      867



      Other, net



      10,650


      (1)


      6,259


      (2)

      Stock-based compensation



      9,895




      7,811



      Adjusted EBITDA


      $

      66,298



      $

      36,386











      Total revenue


      $

      965,100



      $

      620,390











      Adjusted EBITDA margin



      7

      %



      6

      %




      (1)

      Other, net, for the three months ended March 31, 2026, relates to an allowance on receivables that the Company plans to recover from the payer, post-acquisition integration costs, and severance fees incurred.

      (2)

      Other, net, for the three months ended March 31, 2025, relates to debt issuance costs expensed in connection with our Second Amended and Restated Credit Facility, transaction costs for our acquisition of Prospect, certain costs for some of our acquisitions, non-cash changes related to change in the fair value of our call option and collar agreement, and severance fees incurred.

      Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted

      Set forth below are reconciliations of net income to adjusted net income attributable to Astrana as well as the reconciliation to adjusted EPS - diluted for the three months ended March 31, 2026 and 2025.



      Three Months Ended
      March 31,



      (in thousands, except for share and per share data)


      2026



      2025



      Net income


      $

      13,131



      $

      6,221



      (Income) loss from equity method investments



      (1,720)




      867



      Other, net (1)



      10,650




      6,259



      Stock-based compensation



      9,895




      7,811



      Amortization of intangible assets attributable to acquisitions



      13,850




      6,263



      Tax adjustments



      (7,525)


      (2)


      (4,602)


      (3)

      Adjusted net income attributable to non-controlling interests



      (1,928)


      (4)


      (2,317)


      (5)

      Adjusted net income attributable to Astrana Health, Inc.


      $

      36,353



      $

      20,502











      Weighted average shares of common stock outstanding – diluted



      49,054,135




      48,850,666











      Adjusted earnings per share - diluted


      $

      0.74



      $

      0.42





      (1)

      The components of other, net, as set forth in the table above, are described in the footnotes to the table under "Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin". Please see the footnotes to such table for additional information.

      (2)

      Tax adjustments for the three months ended March 31, 2026, includes the tax effect for, at a 27.1% statutory blended tax rate, the adjustments made to net income of $8.9 million, partially offset by 162(m) impact of $1.3 million.

      (3)

      Tax adjustments for the three months ended March 31, 2025, includes the tax effect for, at a 27.1% statutory blended tax rate, the adjustments made to net income of $5.7 million, partially offset by 162(m) impact of $1.1 million.

      (4)

      Includes net loss attributable to non-controlling interests ("NCI") of $1.3 million, offset by adjustments attributable to NCI of $3.2 million, for the three months ended March 31, 2026.

      (5)

      Includes net loss attributable to NCI of $0.5 million, offset by adjustments attributable to NCI of $2.8 million, for the three months ended March 31, 2025.

      Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA




      Year Ending
      December 31, 2026




      Guidance Range


      (in thousands)


      Low



      High


      Net income


      $

      54,000



      $

      74,000


      Interest expense



      51,000




      55,000


      Provision for income taxes



      38,000




      44,000


      Depreciation and amortization



      65,000




      65,000


      EBITDA



      208,000




      238,000









      Income from equity method investments



      (4,000)




      (4,000)


      Other, net



      7,000




      7,000


      Stock-based compensation



      39,000




      39,000


      Adjusted EBITDA


      $

      250,000



      $

      280,000


      The Company has not provided a quantitative reconciliation of EBITDA and Adjusted EBITDA for the quarter ending June 30, 2026 to the most comparable GAAP measure on a forward-looking basis within this press release because the Company is unable, without unreasonable efforts, to provide reconciling information with respect to certain line items that cannot be calculated for the three month period. These items, which could materially affect the computation of forward-looking GAAP net income, are inherently uncertain and depend on various factors, some of which are outside of the Company's control.

      Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow




      Year Ending
      December 31, 2026




      Guidance Range


      (in thousands)


      Low



      High


      Net cash provided by operating activities


      $

      125,000



      $

      145,000


      Cash used in purchases of property and equipment



      (20,000)




      (12,500)


      Free cash flow


      $

      105,000



      $

      132,500


      Use of Non-GAAP Financial Measures

      This press release contains the non-GAAP financial measures EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income attributable to Astrana, and adjusted EPS - diluted, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles ("GAAP") is net income. This press release also contains the non-GAAP financial measure free cash flow, of which the most directly comparable financial measure presented in accordance with U.S. GAAP is net cash provided by operating activities. These measures are not in accordance with, or alternatives to, GAAP, and may be calculated differently from similar non-GAAP financial measures used by other companies. We use Adjusted EBITDA, Adjusted EBITDA margin, adjusted EPS - diluted, and free cash flow as supplemental performance measures of our operations, for financial and operational decision-making, and as supplemental means of evaluating period-to-period comparisons on a consistent basis and, for free cash flow, to reflect the cash flow trends in our business. Adjusted EBITDA is calculated as earnings before interest expense, interest income, income taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, and stock-based compensation. We define Adjusted EBITDA margin as Adjusted EBITDA over total revenue. Adjusted net income attributable to Astrana is calculated as net income, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, amortization of intangible assets attributable to acquisitions, certain tax adjustments, and amounts related to net income or loss attributable to non-controlling interests. We define adjusted EPS - diluted as adjusted net income attributable to Astrana over weighted average shares of common stock outstanding - diluted. We define free cash flow as net cash provided by operating activities minus cash used in purchases of property and equipment.

      We believe the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators we use as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. Other companies may calculate EBITDA, Adjusted EBITDA, adjusted net income attributable to Astrana, adjusted EPS - diluted, and free cash flow differently, limiting the usefulness of these measures for comparative purposes. To the extent this press release contains historical or future non-GAAP financial measures, we have provided corresponding GAAP financial measures for comparative purposes. The reconciliations between certain GAAP and non-GAAP measures are provided above.

      SOURCE Astrana Health, Inc.

      Modal title

      Also from this source

      Foothill Regional Medical Center Recognized Among Healthgrades' 2027 America's 100 Best Hospitals for Orthopedic Surgery and Joint Replacement

      Foothill Regional Medical Center Recognized Among Healthgrades' 2027 America's 100 Best Hospitals for Orthopedic Surgery and Joint Replacement

      Foothill Regional Medical Center, part of Astrana Health, Inc. (NASDAQ: ASTH), earned multiple national honors from Healthgrades, the leading...

      Astrana Health, Inc. Reports Third Quarter 2026 Results

      Astrana Health, Inc. Reports Third Quarter 2026 Results

      Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric,...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Computer & Electronics

      Computer & Electronics

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.